RadarScope: PLSE — Analiza Fundamentala

Market Cap

$3.5B

P/E Ratio

-43.0

Profit Margin

-6755.8%

ROE

-94.4%

📈 Earnings Report — 2026-08

Ultimul trimestru raportat

EPS Actual

$-0.36

▼ 33.3% QoQ▼ 28.6% YoY

EPS Estimat

$-0.31

Miss by 16.1%

Revenue Actual

$0M

▲ 8.5% QoQ

Revenue Estimat

$0M

Miss by 13.2%

Istoric Ultimele 4 Trimestre

2026-08

EPS Actual

$-0.36

EPS Est.

$-0.31

Revenue

$0M

Beat/Miss

Miss by 16.1%

2026-05

EPS Actual

$-0.27

EPS Est.

$-0.32

Revenue

$0M

Beat/Miss

Beat by 15.6%

2026-02

EPS Actual

$-0.26

EPS Est.

$-0.265

Revenue

$0M

Beat/Miss

Beat by 1.9%

2025-11

EPS Actual

$-0.29

EPS Est.

$-0.31

Revenue

$0M

Beat/Miss

Beat by 6.5%

Urmatorul Raport

Data

2026-11-04

EPS Estimat

$-0.35

Revenue Estimat

$1M

📊 Scoruri Companie

Crestere 8/10

Revenue & Profit Growth

Evaluare 3/10

P/E · P/B · P/S

Calitate 3/10

Marje · ROE · Datorii

Risc 8/10

Beta · Market Cap

📈 Date Financiare Istorice in miliarde USD

💰 Revenue

📊 Net Profit

💵 Cash Flow

Operating (albastru) · Free (violet)

🏦 Cash & Datorii

Cash (verde) · Long-term Debt (rosu)

💸 Operating Expenses

🤖 Analiza RadarScope AI

Analiza AI (verdict, bull case, bear case) este disponibila pe planurile Trader si Elite.

💡 Disponibil pe Trader / Elite

🐂 BULL CASE

Disponibil pe Trader / Elite

🐻 BEAR CASE

Disponibil pe Trader / Elite

TINE Upgrade la Trader sau Elite pentru verdictul AI.

📖 Indicatorii lui Lynch — concluzii rapide dupa Peter Lynch

PEG — P/E in contextul cresterii

N/A

PEG indisponibil (profit negativ). PEG-ul Lynch nu se aplica firmelor fara profit sau cu profit in scadere.

P/E vs istoria proprie si sectorul

P/E acum -43.0.
vs sector Healthcare (22.3): SUB sector
Lynch: compara P/E cu propria istorie si media industriei, nu in absolut.

Procentul din vanzari (concentrare produs)

CONCENTRAT PE 1 PRODUS

Cycle Units Products 100%
Lynch: un produs genial care aduce sub ~10% din venituri nu misca actiunea.

Cash si datorie

CASH NET POZITIV

Cash net pe actiune $1.14 (~2% din pret e deja acoperit de bani lichizi).
Datorie/Capital 0.07 DATORIE MICA — decide supravietuirea in vremuri grele (esential la ciclice si turnarounds).
Tip datorie: OK — TERMEN LUNG — majoritar pe termen lung (obligatiuni = timp de manevra). Scurt $1.6M / Lung $0.00.

Marje de profit

MARJE SUBTIRI

Bruta -21.6% · Operationala -7007.8% · Neta -6755.8%. Marje mici — dar intr-o redresare de ciclu, tocmai firma cu marje mici are cea mai exploziva crestere procentuala a profitului.

Povestea in 2 minute

De ce o detii: Analiza AI (verdict, bull case, bear case) este disponibila pe planurile Trader si Elite.
Ce trebuie sa mearga bine: Disponibil pe Trader / Elite
Obstacole: Disponibil pe Trader / Elite
Lynch: daca nu poti explica coerent in 2 minute de ce o detii, nu o intelegi.

🔬 Analiza Fundamentala Avansata · an fiscal 2025-12-31

🏦 Altman Z-Score

146.56 ZONA SIGURA

X1 Capital de lucru / Active	0.799	x1.2
X2 Profit reportat / Active	-4.9	x1.4
X3 EBIT / Active	-0.814	x3.3
X4 Capitalizare / Datorii	258.566	x0.6
X5 Vanzari / Active	0.004	x1.0

Praguri Altman (1968): >2,99 sigur · 1,81–2,99 gri · <1,81 pericol de faliment

💪 Piotroski F-Score

2/9 SLAB

✗ROA pozitiv-76.99%

✗Cash flow operational pozitiv-54.12M

✗ROA in crestere-76.99% vs -40.45%

✓Cash flow > Profit net (calitate)-54.12M vs -72.78M

✓Datorie pe termen lung in scadere0.0% vs 0.0% din active

✗Lichiditate curenta in crestere10.53 vs 11.88

✗Fara emisiune de actiuni noi67.8M vs 65.9M

✗Marja bruta in cresteren/a

✗Rotatia activelor in cresteren/a

9 teste binare (Piotroski, 2000). 8–9 = putere financiara · 0–2 = slabiciune

⚖️ ROIC vs WACC

-828.60pp DISTRUGE VALOARE

ROIC (randamentul capitalului)	-815.75%
WACC (costul capitalului)	12.85%

Ipoteze (la vedere):
Rata fara risc 4.2% (USD) · Beta 1.58 · Prima de risc 5.5%
Cost capitaluri proprii 12.87% · Cost datorie 1.0% · Impozit efectiv 21.0%

Metode publice: Altman, E. (1968), Journal of Finance · Piotroski, J. (2000), Journal of Accounting Research · ROIC/WACC prin CAPM. Fiecare cifra isi arata componentele si pragurile — poti reface calculul manual.

📊 Metrici Fundamentale

P/E TTM-43.0

P/B TTM35.00

P/S TTM2939.51

EV/EBITDA-42.4

Gross Margin-21.6%

Operating Margin-7007.8%

Net Margin-6755.8%

ROE-94.4%

ROA-69.3%

Debt/Equity0.07

Current Ratio9.63

FCF Yield-1.8%

Dividend Yield—

Beta1.58

💰 Venituri & Profit (ultimele trimestre)

Trimestru	Revenue	Gross Profit	Net Income	EPS
2026-06	$434000.00	$161000.00	$-24.7M	$-0.36
2026-03	$401000.00	$31000.00	$-18.6M	$-0.26
2025-12	$264000.00	$-255000.00	$-17.4M	$-0.26
2025-09	$86000.00	$-193000.00	$-19.4M	$-0.29

🏢 Profil Companie

CEOPaul Arthur LaViolette

Angajati116

IPO2016-05-18

Websitehttps://www.pulsebiosciences.c...

52W High$50.90

52W Low$12.56

Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. ...

🎯 Score Breakdown

Calitate Companie (Q) 3/10

Risc Speculativ (R) 8/10

Scor AI RadarScope 0/100

VERDICT FINAL

TINE

Upgrade la Trader sau Elite pentru verdictul AI.

🔒 Analiza completa disponibila cu cont SignalRadar